Lothar Bergmann born on November 17, 1949, in Seligenstadt Hessen. He made his medical examination at the J.W. Goethe University in Frankfurt/FRG on July 2, 1976, and became a specialist in internal medicine on September 18, 1985, and a specialist in hematology and medical oncology on January 20, 1988. On January 1991, he became a Professor of internal medicine at the J.W. Goethe University in Frankfurt. He has more than 30 years of experience in performing clinical phase I-III trials as principal investigator and LKP. Presently, he is an Assistant Medical Director of the Medical Clinic II (Hematology/Oncology) of the University Hospital of the J.W. Goethe University in Frankfurt and chairs the “Tumorzentrum Rhein-Main.” Clinically, he focuses on the therapies of lymphomas and leukemias and solid tumors (e.g., renal cell cancer, pancreatic cancer, CLL) as well. Scientifically, he deals with tumor suppressor gene and oncogene regulation, apoptosis in cancer cells, and immune regulation. He is a member of many international societies as the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), the European Society of Medical Oncology (ESMO), the European Hematology Association (EHA), the International Society of Experimental Hematology (ISEH), and the American Society of Hematology (ASH). Additionally, he is a member of various German Societies as the German Society of Haematology and Oncology (DGHO), the German Cancer Society (DKG) and Study Group for Medical Oncology (AIO), and the German Society of Internal Medicine. He chairs the Interdisciplinary Study Group for Renal Cell Cancer of the DKG and has been since 2001 the Secretary of the Biotherapy Development Association (BDA). He is a Member of the “off-label” Commission of the BfArm and a Core Member of the Scientific Advisory Group Oncology (SAG-Oncology) of the European Medicine Agency (EMEA).
Biography Updated on 23 March 2009